Skip to content

Evaluation of acute and long-term outcomes of lysis therapy of arterial occlusions with tissue-specific plasminogen activator (rt-PA).

Evaluation of acute and long-term outcomes of lysis therapy of arterial occlusions with tissue-specific plasminogen activator (rt-PA).

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00030930
Enrollment
1238
Registered
2022-12-16
Start date
2022-12-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I70.20

Interventions

Group 1: All patients treated with lysis therapy for peripheral arterial disease of the lower extremities

Sponsors

Universitäts-Herzzentrum Freiburg-Bad Krozingen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All patients treated with lysis therapy for peripheral arterial disease of the lower extremities

Exclusion criteria

Exclusion criteria: - Patients in whom lysis therapy has not been used. - Patients in whom lysis therapy has been used for recanalization of deep vein thrombosis or upper extremity vascular occlusion.

Design outcomes

Primary

MeasureTime frame
-Peri-interventional complication rate defined as complications that affected therapy or required surgical or other correction, or prolonged hospital stay. Complications are divided into Serious Adverse Event (SAE) and (Adverse Event) AE. - Acute Intervention Success, i.e., establishment of blood flow in the lysed vessel area defined as complete clearance of the occlusion or sufficient clearance to reveal an underlying etio- logical factor that was responsible for the occlusion.

Secondary

MeasureTime frame
- Predictors of complication - Leg preservation acutely and after 6, 12 and 24 months - Re-intervention rate at the target lesion ("target lesion revascularization", TLR) and at the target vessel ("target vessel revascularization", TVR) - Change in clinical symptoms using the Rutherford-Becker classification at 6, 12, and 24 months - Change of the Ankle-Brachial-Index after 6, 12 and 24 months

Countries

Germany

Contacts

Public ContactThomas Zeller

Universitäts-Herzzentrum Freiburg-Bad Krozingen

thomas.zeller@uniklinik-freiburg.de+4976334020

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026